SecBot SecBot
SECBOTREPLAY Home › Report › URGN

URGN · UroGen Pharma entered into an Option and Research License Agreement…

UroGen Pharma Ltd. · 8-K filed Aug 20, 2026 at 07:04 ET

At the news

NEUTRALIMPACT 4/10

8-K filed Aug 20, 2026 at 07:04 ET

UroGen Pharma entered into an Option and Research License Agreement with IntraGel Therapeutics, securing an exclusive option for a worldwide license to develop and commercialize IntraGel's TumoCure product (using its SRGel sustained-release hydrogel platform) for advanced head and neck cancer, plus options for additional combination products. UroGen also agreed to invest up to $7,000,000 in IntraGel's equity. This is an early-stage, pre-clinical pipeline expansion into a new oncology indication with modest financial commitment, providing optionality without near-term revenue impact.

  • UroGen obtained an exclusive option for a worldwide license to develop and commercialize IntraGel's TumoCure product for advanced head and neck cancer.
  • UroGen also obtained options for exclusive worldwide licenses to develop additional products combining IntraGel's SRGel platform with compounds designated by UroGen.
  • UroGen agreed to invest up to $7,000,000 in IntraGel's equity securities.
  • The agreement was entered into on August 18, 2026.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access